Revolutionizing the Healthcare Industry

Interview with Dr. med. Horst Mertens, COO and CBDO of Emperra GmbH E-Health Technologies

Emperra GmbH E-Health Technologies ESYSTA Product System
A central product of Emperra GmbH is the ESYSTA product system, which seamlessly records and processes insulin units and blood glucose readings

E-Health Technologies are revolutionizing the healthcare industry by providing digital solutions that benefit both patients and doctors alike. Emperra GmbH E-Health Technologies is at the forefront of this development with its ESYSTA platform, which stands for a personalized and efficient healthcare provision for patients with diabetes.

Particularly in the treatment of chronic diseases such as diabetes, digital technologies open up new possibilities for personalized and efficient healthcare. With their innovative platform that allows seamless integration of data and improved patient care, Emperra GmbH E-Health Technologies is driving progress in healthcare and offering pioneering approaches to the global challenges of modern medicine.

Optimized Diabetes Therapy

Emperra GmbH has established itself as an innovative company in the field of digital health solutions, especially with a strong focus on diabetes treatment. Under the leadership of Dr. med. Horst Mertens, the Chief Operating Officer and Chief Business Development Officer, the company has made significant progress in recent years. Emperra GmbH started in hardware development before increasingly turning to digital medicine.

Dr. med. Horst Mertens, COO and CBDO of Emperra GmbH E-Health Technologies
Dr. med. Horst Mertens, COO and CBDO of Emperra GmbH E-Health Technologies

A central development of the company is the ESYSTA product system, which seamlessly stores insulin units and blood glucose readings and automatically transfers them to a digital diary. "Patients have access to their diabetes data at any time via the ESYSTA portal and the associated app, and authorized medical professionals can adjust the therapy based on this data," explains Dr. Horst Mertens. "ESYSTA is the only platform in the world to capture both blood sugar and insulin values, which allows for optimized therapy management."

Establishing ESYSTA in the market

Another unique feature of ESYSTA is the interoperability of the portal. It is compatible with more than 90% of all hardware components in the market and can process their digital signals, which significantly improves the quality of care. A personalized traffic light algorithm, based on artificial intelligence, allows doctors to efficiently monitor the data of many patients, which is invaluable given the limited time resources in the medical field. However, Emperra GmbH also faces significant challenges. The approval of their products by the relevant authorities is a complex process that requires a lot of time and resources. "Start-ups in the life sciences and health care are often founded by highly intelligent people," says Dr. Horst Mertens. "However, they often lack focus on commercialization and market penetration. This was one of the reasons why I came to Emperra. I use my many years of experience to specifically strengthen this area."

Emperra GmbH E-Health Technologies Interoperability
Unique selling point of ESYSTA: the interoperability of the portal, which is compatible with more than 90% of all hardware components and can process their digital signals

The company plans to launch its digital platform in January 2025, with a focus on patient-centered marketing. In Germany, where the middle class is traditionally strong, the company faces the challenge of serving global markets with its own resources. "For this, we need to approach serious global companies that will invest in Emperra to drive international expansion," says the COO and CBDO. The German market serves as a pilot market, and the strategic next step is expansion into France, Austria, and Belgium. Subsequently, four Arab countries will be targeted, as the proportion of people suffering from diabetes is particularly high there. In the long term, Emperra plans to conduct clinical trials in the USA to also penetrate this important market.

"Our motivation is clearly to help people with our digital diabetes treatment platform," emphasizes Dr. Horst Mertens. "If we successfully establish our ESYSTA system in the market, we can make life easier for many patients. Humanity is increasingly suffering from high-prevalence chronic diseases, with diabetes mellitus increasingly playing a central role. If blood sugar levels are not quickly and sustainably normalized, many complications can arise. Here, we want to utilize our platform to bring about real improvement. Our greatest strength lies in our team. We have a highly specialized, dedicated team of smart minds."

More Articles on Topic

Efficient staff scheduling with the app

Interview with Oliver Huber CCO of R&R WFM B.V.

Efficient staff scheduling with the app

Staff scheduling in retail grocery is not easy. The mix of permanent staff and temporary workers, long opening hours, and the need for flexibility...

Window to the Future

Interview with Miriam Berzen, Managing Director of Klaes GmbH & Co. KG

Window to the Future

When Horst Klaes developed a software solution for free window design in 1983, he laid the foundation for a company that is today a global leader...

Biotechnology for Animals and Humans

Interview with Dr. Christina Boss, CEO of SAN Group Biotech Germany GmbH

Biotechnology for Animals and Humans

Modern diagnostics and vaccine development play a central role in animal health - and thus also in consumer protection. With state-of-the-art diagnostics:::

A Comprehensive Treatment

Interview with Prof. Dr. med. Martin Kriegmair, Managing Director of Medical Team Clinic GmbH

A Comprehensive Treatment

The Munich-Planegg Urological Clinic offers its patients the entire spectrum of surgical treatments including all adjunctive therapies...

Manfred Brinkmann, Managing Editor-in-Chief

Manfred Brinkmann

Managing Editor of European Business

Are You Shaping the Future of Business?

As Managing Editor-in-Chief, I am always searching for the next generation of leaders and innovators. If you are at the helm of a company making a significant impact, I invite you to connect with us. Let's share your vision with our audience of influentia.